Furberg CD - Search Results

1

Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.

Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD. Miller M, et al. Among authors: furberg cd. Arch Intern Med. 2000 Feb 14;160(3):343-7. doi: 10.1001/archinte.160.3.343. Arch Intern Med. 2000. PMID: 10668836 Clinical Trial.

2

Reductase inhibitor monotherapy and stroke prevention.

Crouse JR 3rd, Byington RP, Hoen HM, Furberg CD. Crouse JR 3rd, et al. Among authors: furberg cd. Arch Intern Med. 1997 Jun 23;157(12):1305-10. Arch Intern Med. 1997. PMID: 9201004

3

Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).

Byington RP, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, Hunninghake DB, Mancini GB. Byington RP, et al. Among authors: furberg cd. Am J Cardiol. 1997 Oct 15;80(8):1087-90. doi: 10.1016/s0002-9149(97)00611-5. Am J Cardiol. 1997. PMID: 9352986

4

Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

Byington RP, Evans GW, Espeland MA, Applegate WB, Hunninghake DB, Probstfield J, Furberg CD. Byington RP, et al. Among authors: furberg cd. Circulation. 1999 Jul 20;100(3):e14-7. doi: 10.1161/01.cir.100.3.e14. Circulation. 1999. PMID: 10411862 Clinical Trial.

5

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators.

Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Pitt B, et al. Among authors: furberg cd. Circulation. 2000 Sep 26;102(13):1503-10. doi: 10.1161/01.cir.102.13.1503. Circulation. 2000. PMID: 11004140 Clinical Trial.

6

Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.

Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME. Furberg CD, et al. Am J Cardiol. 1995 Sep 28;76(9):60C-63C. doi: 10.1016/s0002-9149(99)80472-x. Am J Cardiol. 1995. PMID: 7572689 Clinical Trial.

7

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.

Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Sacks FM, et al. Among authors: furberg cd. Circulation. 2000 Oct 17;102(16):1893-900. doi: 10.1161/01.cir.102.16.1893. Circulation. 2000. PMID: 11034935 Clinical Trial.

8

Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience.

Byington RP, Worthy J, Craven T, Furberg CD. Byington RP, et al. Among authors: furberg cd. Am J Cardiol. 1990 Jun 1;65(20):1287-91. doi: 10.1016/0002-9149(90)91314-v. Am J Cardiol. 1990. PMID: 2188492 Clinical Trial.

9

Reversing risk in coronary disease.

Byington RP, Furberg CD. Byington RP, et al. Among authors: furberg cd. Lancet. 1995 Feb 4;345(8945):330. doi: 10.1016/s0140-6736(95)90323-2. Lancet. 1995. PMID: 7837897 No abstract available.

10

Lessons learned from clinical trials with ultrasound end-points.

Furberg CD, Byington RP, Craven TE. Furberg CD, et al. J Intern Med. 1994 Nov;236(5):575-80. doi: 10.1111/j.1365-2796.1994.tb00848.x. J Intern Med. 1994. PMID: 7964436 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

411 results

Search Page